Association of Metabolic Comorbidities with Pediatric Psoriasis: A Systematic Review and Meta-Analysis

Background: An evident relationship has been shown between psoriasis and metabolic comorbidities. However, the results in pediatric psoriasis vary from study to study, and no meta-analysis exists on the association of metabolic comorbidities with pediatric psoriasis. Objective: To evaluate the association between psoriasis and metabolic comorbidities in pediatric patients. Methods: We searched articles published in PubMed, EMBASE, and Cochrane Library databases from inception to April 30, 2019. All observational studies reporting the prevalence of obesity or metabolic comorbidities in pediatric patients with psoriasis were included. Results: The meta-analysis included 16 unique studies meeting the inclusion criteria. The pooled odds ratios in pediatric patients with psoriasis was 2.40 (95% confidence interval [CI], 1.60 similar to 3.59) for obesity (13 studies), 2.73 (95% CI, 1.79 similar to 4.17) for hypertension (8 studies), 2.01 (95% CI, 1.09 similar to 3.73) for diabetes mellitus (8 studies), 1.67 (95% CI, 1.42 similar to 1.97) for dyslipidemia (7 studies), and 7.49 (95% CI, 1.86 similar to 30.07) for metabolic syndrome (4 studies). Conclusion: Pediatric patients with psoriasis showed a significantly higher prevalence of obesity, hypertension, diabetes, dyslipidemia, and metabolic syndrome. Adequate monitoring and timely management of metabolic comorbidities should be considered in these patients.